StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Aristotle testing volumes and daily schedule

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Jan 25, 2022 11:19am

152 Views

Post# 34358119

RE:RE:RE:Aristotle testing volumes and daily schedule

Lith, still can't get over your calculation, and how conservative it is.
It's based on website bookings in the U.S. and Canada alone. Add to that phone bookings, and then add the patients who decide to forego the free consultation and go right into treatment...
And the U.K...
Your very restrained, conservative figures need to be doubled and even tripled to reflect what's really going on... Which makes SZLS the sleeper stock in my portfolio...
Looking forward to great things in the next couple of quarters...
GLTA longs!

LithLover wrote:
Nope. I think 2/3 of people booking a consult is reasonable to follow through with a test. But let's say only 1/3 book and it's only 5 tests per day thats 30 a week. $3 million a year from Aristotle. $4 million from Care. $7 million and say the industry valuation is on the low end of the 10-14 times revenue Still $70 million valuation

Doesn't account for covid or any other revenues and still values us at $0.80/share. $0.80 on the low side $1.60 on the high

I don't expect these numbers to show in Q4 for March 31 but Q1 2022 for mid May should be reflected.

brad129 wrote: That's a lot of assumptions, don't you think?